Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd. (QNTM) generates news across clinical development, capital markets, licensing, and legal proceedings, reflecting its role as a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse disorders. Many of its recent announcements center on Lucid-21-302 (Lucid-MS), a patented new chemical entity developed through its subsidiary Lucid Psycheceuticals Inc. News items describe progress in toxicity and toxicokinetic studies, Phase 1 clinical work, and preparations for an Investigational New Drug (IND) application with the U.S. FDA, as well as a joint PET imaging study with Massachusetts General Hospital scientists to monitor myelin integrity in multiple sclerosis.
Investors following QNTM news will also see updates on financial results, balance sheet developments, and capital structure changes, including private placements, warrant expirations, at-the-market offering agreements, and the issuance of contingent value rights (CVRs) linked to potential recoveries from litigation. The company’s disclosures highlight its digital asset portfolio, comprised mainly of Bitcoin and other cryptocurrencies, and provide commentary on realized gains and treasury management.
Another recurring theme in Quantum BioPharma’s news flow is its relationship with Unbuzzd Wellness Inc., licensee of the unbuzzd asset. Press releases cover Unbuzzd Wellness Inc.’s capital raising plans, investor webinars, and positioning of unbuzzd as a beverage or supplement aimed at alcohol metabolism and related symptoms, while noting Quantum BioPharma’s equity stake and royalty rights.
In addition, Quantum BioPharma issues updates on its lawsuit alleging stock market manipulation and stock spoofing involving major financial institutions, including coverage by investigative news program W5. These items outline the company’s allegations, the scale of the claimed damages, and the link between the litigation and the CVR structure. For readers and investors, the QNTM news stream offers a consolidated view of clinical milestones, financial reporting, licensing activity, and legal developments related to Quantum BioPharma.
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency portfolio with an additional USD $1,500,000 investment in Bitcoin (BTC) and other cryptocurrencies, following Board approval. This strategic move brings the company's total crypto investment to USD $3,500,000.
The company will continue accepting future financings and transactions in cryptocurrency, viewing it as a potential hedge against the dollar and an opportunity for shareholder returns. All crypto assets are held with a compliant custodian, and transactions adhere to financial and audit regulations. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions.
Quantum BioPharma (NASDAQ: QNTM) has successfully completed its Phase 1 Multiple Ascending Dose clinical trial for Lucid-21-302 (Lucid-MS), a novel multiple sclerosis drug. The Safety Review Committee confirmed the drug was well-tolerated with no safety concerns or serious adverse events reported.
Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound featuring a unique mechanism of action. Preclinical models demonstrated its ability to stabilize the myelin sheath surrounding nerve fibers, potentially protecting against demyelination - a key characteristic of MS that leads to progressive disability.
Following this milestone, the company is preparing to advance to Phase 2 trials in MS patients, moving closer to their goals of drug approval and commercialization.
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency holdings with an additional USD $1,000,000 investment in Bitcoin (BTC) and other cryptocurrencies, bringing its total crypto investment to USD $2,000,000. The investment, approved by the Board of Directors, is part of the company's strategic efforts to hedge against the Canadian dollar and potentially provide returns for shareholders.
The company has established infrastructure to accept cryptocurrency for financing and other transactions, with all digital assets being held by a fully compliant custodian. Quantum BioPharma emphasizes its commitment to maintaining compliance with financial and audit regulations while reserving the right to adjust its cryptocurrency holdings based on market conditions.
Quantum BioPharma (NASDAQ: QNTM) has engaged MZ Group to lead its strategic investor relations and financial communications program. MZ will develop and implement a comprehensive capital markets strategy to increase the company's visibility in the investment community.
The company is developing products focused on brain disorders and alcohol health, including unbuzzd™ and rekvry™, which address excessive alcohol use - a problem costing the U.S. approximately $249 billion annually. Additionally, Quantum is working on a potential first-in-class treatment for demyelinating diseases, including Multiple Sclerosis, which affects nearly 1 million people in the U.S. and 2.8 million worldwide.
The MZ engagement involves a two-month initial period at $10,000 per month, with automatic monthly renewals thereafter. The agreement can be terminated by either party with fifteen days' notice.
Quantum BioPharma (NASDAQ: QNTM) has announced the engagement of two agencies to enhance its public relations and investor awareness programs. Enterprise Canada has been retained indefinitely from December 18, 2024, with a structured payment plan including C$10,000 for Phase 1, C$2,500 upon completion, and C$5,000 monthly retainer for Phase 3. They will develop the company's narrative and media relations strategy.
Empire Market Ventures has been engaged for three months from February 7, 2025, for US$25,000, to provide investor awareness services including access to exclusive mailing lists and content creation.
The company highlighted its key products: unbuzzd™, a rapid alcohol detoxification beverage; rekvry™ for alcohol misuse treatment in healthcare settings; and LUCID-21-302, a new chemical entity targeting multiple sclerosis. The CEO announced that unbuzzd™'s RTD formulation is expected in Q1 2025, following successful clinical trials.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition , developer of unbuzzd™ (a beverage that accelerates alcohol metabolism), has engaged a leading New York Investment Bank to raise up to $10 million USD and explore an IPO on a major US exchange.
Quantum BioPharma owns 25.71% of Celly Nutrition and receives 7% royalty on unbuzzd™ sales until reaching $250 million, after which it drops to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses.
The Letter of Engagement signed on February 4, 2025, covers financial advisory services for a potential Go-Public Transaction and managing the proposed public offering. Celly Nutrition plans to use the capital to accelerate marketing, retail, and direct-to-consumer sales development of unbuzzd™.
Quantum BioPharma (NASDAQ: QNTM) has announced successful results from a double-blind, randomized, placebo-controlled clinical trial for unbuzzd™, their dietary supplement designed to combat alcohol intoxication effects. The study demonstrated that unbuzzd™ accelerated blood alcohol concentration (BAC) reduction by over 40% within 30 minutes compared to placebo.
Key findings showed statistically significant improvements in:
- Alcohol metabolism acceleration
- Enhanced alertness within 30 minutes
- Stabilized heart rate and blood pressure
- Reduced perceived impairment and mental fatigue
- 67% reduction in hangover headache severity
The trial included participants aged 21-43 of both genders, with weights ranging from 119-232 pounds. The product showed no adverse effects and was well-tolerated by all participants. unbuzzd™ is currently licensed to Celly Nutrition Corp. and available for purchase.
Quantum BioPharma (NASDAQ:QNTM) announced upcoming court proceedings against former CEO Dr. Raza Bokhari on January 24, 2025, seeking to declare him a vexatious litigant. The company has previously won multiple legal battles against Bokhari, who was terminated for cause in July 2021, resulting in approximately $3 million in awards in favor of Quantum BioPharma.
An arbitrator dismissed Bokhari's wrongful dismissal claim and awarded the company CDN$2.81 million plus interest. Additional court costs awarded include $175,000 from Justice Conway and $5,000 from the Court of Appeal. The U.S. District Court granted judgment in favor of Quantum BioPharma, including various monetary awards with interest rates ranging from 4% to 6%. Bokhari has appealed this judgment and provided a supersedeas bond for USD $2,882,441.48 pending the United States Court of Appeals decision.
Quantum BioPharma (NASDAQ:QNTM) announces its dual listing on Upstream, a MERJ Exchange market and global securities trading app, starting January 14, 2025, at 10:00am EST. The company, focused on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, will maintain its listings on Nasdaq, Canadian Securities Exchange, and Frankfurt exchanges.
The Upstream platform operates 20 hours daily, offering real-time trading and settlement with transparent orderbook features. Non-U.S. investors can access QNTM shares through the Upstream app after completing KYC verification. Trading will begin once an existing shareholder places a sale offer.
CEO Zeeshan Saeed states this dual listing aims to add value and liquidity while expanding their reach to a global investor base. U.S. persons are restricted from depositing, buying, or selling securities on Upstream.
Quantum BioPharma (NASDAQ:QNTM) has received approval for dual listing on Upstream, a MERJ Exchange market and global securities trading app. Trading will commence on January 14, 2025, at 10:00am ET under the ticker 'QNTM'. The dual listing aims to provide access to a global investor base outside the U.S., enabling trading through various payment methods including credit/debit cards, PayPal, USD, or USDC.
The Upstream platform operates 20 hours daily, 7 days a week, featuring real-time trading and settlement with a transparent orderbook designed to prevent market manipulation. Non-U.S. investors can participate by downloading the Upstream app, completing KYC verification, and following specific share transfer procedures.
The company, which focuses on developing treatments for neurodegenerative and metabolic disorders, views this dual listing as a strategic move to enhance shareholder value by increasing liquidity and improving price discovery.